The global mRNA vaccines and therapeutics market was valued at US$ 19.6 Bn in 2023 and is anticipated to reach US$ 85.9 Bn by the end of 2034, expanding at a CAGR of 14.6% from 2024 to 2034. The market is witnessing substantial growth owing to the increasing prevalence of chronic diseases, rapid advancements in messenger RNA technology, growing investments in biotechnology research, and rising collaborations between pharmaceutical companies, academic institutions, and research organizations.

Market Size & Highlights

The global mRNA vaccines and therapeutics market reached US$ 19.6 Bn in 2023 and is projected to attain US$ 85.9 Bn by 2034. The industry is expected to expand at a CAGR of 14.6% during the forecast period.

North America held the leading share of the global market in 2023 due to strong research infrastructure, increasing regulatory approvals, and the presence of major biotechnology and pharmaceutical companies. By mRNA type, nucleoside-modified mRNA accounted for a significant market share owing to its enhanced stability, improved protein expression, and reduced immunogenicity.

Leading companies operating in the market include Moderna, Inc., BioNTech SE, CureVac SE, Arcturus Therapeutics, Inc., Sanofi, GSK plc, Argos Therapeutics Inc., Ethris, Pfizer Inc., and AstraZeneca.

Analysts’ Viewpoint on the Global mRNA Vaccines and Therapeutics Market

The mRNA vaccines and therapeutics market is experiencing remarkable growth as messenger RNA technology continues to revolutionize modern medicine. The successful commercialization of mRNA-based COVID-19 vaccines demonstrated the potential of this platform and accelerated investments in next-generation therapeutic applications.

The versatility of mRNA technology enables rapid development of vaccines and therapeutics for infectious diseases, oncology, rare genetic disorders, autoimmune diseases, and other complex medical conditions. Pharmaceutical and biotechnology companies are actively expanding their research programs to explore broader clinical applications beyond infectious disease prevention.

Continuous advancements in lipid nanoparticle (LNP) delivery systems, self-amplifying RNA platforms, and manufacturing technologies are improving the stability, efficacy, and scalability of mRNA-based products. Furthermore, increasing collaborations between industry participants and academic institutions are accelerating innovation and clinical development activities.

As precision medicine gains prominence, mRNA therapeutics are expected to play an increasingly important role in delivering personalized treatment approaches tailored to individual patient needs. Consequently, the market is poised for substantial expansion over the coming decade.

Market Introduction

Messenger Ribonucleic Acid (mRNA) serves as a genetic blueprint that carries instructions from DNA to cellular machinery responsible for protein synthesis. Scientists have leveraged this natural biological process to develop vaccines and therapeutics capable of directing cells to produce specific proteins that stimulate immune responses or treat disease conditions.

mRNA vaccines and therapeutics are developed using advanced biotechnology platforms and can be engineered to encode antigens, therapeutic proteins, or immune-modulating molecules. Once administered, the mRNA enters cells and instructs them to produce target proteins, triggering desired biological responses.

Several forms of mRNA technologies are currently under development, including nucleoside-modified mRNA, unmodified mRNA, self-amplifying mRNA, non-replicating mRNA, and self-replicating RNA platforms. These technologies offer unique advantages such as rapid development timelines, scalable manufacturing processes, and the ability to address a broad range of diseases.

The increasing success of mRNA-based products in clinical and commercial settings has established the technology as one of the most promising therapeutic platforms in the biopharmaceutical industry.

Rising Prevalence of Chronic Diseases Driving Market Growth

The growing burden of chronic diseases worldwide represents one of the most significant factors driving demand for mRNA vaccines and therapeutics. Chronic conditions such as cancer, cardiovascular diseases, diabetes, autoimmune disorders, and respiratory diseases continue to impose substantial healthcare and economic burdens across global populations.

Lifestyle-related risk factors including tobacco consumption, unhealthy dietary habits, physical inactivity, and excessive alcohol consumption contribute significantly to the rising incidence of chronic illnesses. As healthcare systems face increasing pressure to address these conditions, the need for innovative and effective treatment approaches continues to grow.

According to projections from health organizations, the prevalence of chronic diseases is expected to increase steadily over the coming decades. In the United States, the population aged 50 years and above suffering from at least one chronic condition is projected to increase substantially by 2050.

mRNA therapeutics offer several advantages in addressing chronic diseases. Unlike traditional protein therapies that often require repeated administration, mRNA therapies enable cells to produce therapeutic proteins internally, potentially providing more sustained biological effects. This capability creates opportunities for treating complex and previously difficult-to-manage diseases.

Furthermore, mRNA technology can be adapted to target specific genetic and molecular pathways, supporting the development of highly personalized therapeutic solutions. As demand for precision medicine continues to increase, mRNA-based treatments are expected to become increasingly important across multiple therapeutic areas.

Growing R&D Activities and Industry-Academia Collaborations Fueling Market Expansion

The expansion of research and development activities is significantly accelerating innovation within the mRNA vaccines and therapeutics market. Pharmaceutical companies, biotechnology firms, research institutions, and academic organizations are investing heavily in the development of next-generation mRNA technologies.

A major focus area involves improving lipid nanoparticle delivery systems, which play a crucial role in protecting mRNA molecules and ensuring efficient cellular delivery. Advances in delivery technologies are enabling researchers to target specific tissues and organs more effectively while minimizing side effects.

Strategic collaborations between industry participants and academic institutions are further strengthening innovation capabilities. These partnerships combine scientific expertise, technological resources, and clinical development capabilities to accelerate the translation of laboratory discoveries into commercial products.

In August 2023, Gritstone bio entered into a strategic agreement with Genevant Sciences to access advanced lipid nanoparticle technologies for the development and commercialization of self-amplifying RNA vaccines. Such collaborations highlight the industry's commitment to expanding the therapeutic potential of mRNA platforms.

Similarly, in January 2023, Arcturus Therapeutics announced regulatory approval to initiate a Phase 1 clinical study for ARCT-032, an inhaled investigational mRNA therapy designed to treat cystic fibrosis. These developments underscore the expanding scope of mRNA applications beyond vaccines and into therapeutic interventions for rare and chronic diseases.

As investments continue to increase and collaborative ecosystems expand, the pace of innovation in the mRNA sector is expected to accelerate significantly throughout the forecast period.

Segment Analysis

By mRNA Type

The market is segmented into nucleoside-modified mRNA, unmodified mRNA, and self-amplifying mRNA.

Nucleoside-modified mRNA represents a major segment due to its enhanced stability and reduced activation of unwanted immune responses. These characteristics improve therapeutic effectiveness and support broader clinical applications.

Self-amplifying mRNA technologies are gaining considerable attention because they require lower doses while achieving higher protein expression levels. This feature can potentially reduce manufacturing costs and improve scalability for future products.

By Type

Based on type, the market is classified into prophylactic and therapeutic applications.

Prophylactic mRNA vaccines currently account for a substantial share of the market due to the success of COVID-19 vaccines and ongoing development programs targeting influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), and other infectious diseases.

The therapeutic segment is expected to witness strong growth as researchers advance mRNA-based treatments for oncology, rare diseases, cardiovascular disorders, and autoimmune conditions.

By Application

The application segment includes infectious diseases, oncology, rare genetic diseases, and other therapeutic areas.

Infectious diseases remain a dominant application area owing to the proven effectiveness of mRNA vaccine platforms. However, oncology is emerging as one of the most promising growth segments as companies develop personalized cancer vaccines and immune-based cancer therapies.

Rare genetic diseases also present substantial opportunities due to the ability of mRNA therapies to replace missing or defective proteins associated with inherited disorders.

Regional Outlook

North America dominated the global mRNA vaccines and therapeutics market in 2023 and is expected to maintain its leading position throughout the forecast period.

The region benefits from advanced biotechnology infrastructure, robust funding mechanisms, supportive regulatory frameworks, and a strong concentration of pharmaceutical and biotechnology companies. Regulatory approvals for mRNA-based vaccines developed by Pfizer-BioNTech and Moderna significantly strengthened the region’s market position.

Government-sponsored vaccination programs, increasing healthcare expenditures, and strong public-private partnerships continue to support market growth across the United States and Canada.

Europe represents another significant market due to extensive research activities and favorable regulatory support for innovative therapies. Countries such as Germany, the United Kingdom, and France are actively investing in biotechnology research and manufacturing capabilities.

Asia Pacific is anticipated to witness the fastest growth during the forecast period. Rising healthcare investments, expanding biotechnology sectors, increasing clinical trial activities, and growing government support for advanced therapeutic technologies are driving regional market expansion.

Analysis of Key Players

The competitive landscape of the mRNA vaccines and therapeutics market is characterized by intense research activity, strategic collaborations, licensing agreements, and substantial investments in platform technologies.

Major companies are focusing on expanding product pipelines, improving delivery technologies, enhancing manufacturing capabilities, and developing novel therapeutic applications beyond infectious diseases.

Key market participants include Moderna, Inc., BioNTech SE, CureVac SE, Arcturus Therapeutics, Inc., Sanofi, GSK plc, Argos Therapeutics Inc., Ethris, Pfizer Inc., and AstraZeneca.

These companies are continuously strengthening their positions through innovative product development, strategic partnerships, and expansion into new therapeutic areas.

Key Developments

In December 2022, CSL Limited announced that its subsidiary CSL Seqirus finalized a global collaboration and licensing agreement with Arcturus Therapeutics Holdings Inc. The agreement provides access to Arcturus' self-amplifying mRNA vaccine platform technology, which demonstrated positive Phase III clinical trial results for a COVID-19 vaccine candidate.

In December 2022, Moderna received Emergency Use Authorization from the U.S. Food and Drug Administration for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, for children aged six months through five years. The authorization represented another important milestone in the commercialization of advanced mRNA vaccine technologies.

These developments demonstrate the continued expansion of mRNA technology applications and highlight the industry's commitment to advancing next-generation therapeutics and vaccines.

Future Outlook

The future of the mRNA vaccines and therapeutics market remains highly promising as scientific advancements continue to expand the potential applications of messenger RNA technology. Innovations in delivery systems, self-amplifying RNA platforms, personalized medicine approaches, and manufacturing processes are expected to drive the next phase of market growth.

Increasing investments in oncology, rare disease therapies, autoimmune disorders, and regenerative medicine are broadening the scope of mRNA applications beyond infectious disease prevention. At the same time, advances in artificial intelligence, computational biology, and genomic research are accelerating therapeutic discovery and development.

As healthcare systems increasingly prioritize personalized and precision medicine, mRNA-based technologies are expected to become an integral component of future therapeutic strategies. Supported by strong clinical pipelines, expanding regulatory support, and growing industry collaboration, the global mRNA vaccines and therapeutics market is positioned for sustained growth through 2034 and beyond.